Compositions and methods for reactivating latent immunodeficiency virus
AssigneeThe J. David Gladstone Institutes
InventorsMelanie Ott, Daniela Boehm
Life of this patent
Estimating the term…
Abstract
The present disclosure provides compositions and methods for reactivating latent immunodeficiency virus and/or reducing transcription of HIV integrated into the genome of an HIV-infected cell. The present disclosure provides compositions and methods for treating an immunodeficiency virus infection.
Claims31
-23. (canceled)
A method of reactivating latent human immunodeficiency virus (HIV) integrated into the genome of a cell infected with HIV, the method comprising contacting the cell with a SET domain-containing methyltransferase inhibitor that reactivates latent HIV integrated into the genome of the cell.
A method of reducing the number of cells containing a latent human immunodeficiency virus in an individual, the method comprising administering to the individual an effective amount of a SET domain-containing methyltransferase inhibitor that reactivates latent HIV integrated into the genome of one or more cells in the individual.
A method of treating a human immunodeficiency virus (HIV) infection in an individual, the method comprising:
- administering to an individual an effective amount of a first active agent, wherein the first active agent is a SET domain-containing methyltransferase inhibitor that reactivates latent HIV integrated into the genome of a cell in the individual;
- and
- administering to the individual an effective amount of a second active agent, wherein the second active agent inhibits an immunodeficiency virus function selected from viral replication, viral protease activity, viral reverse transcriptase activity, viral entry into a cell, viral integrase activity, viral Rev activity, viral Tat activity, viral Nef activity, viral Vpr activity, viral Vpu activity, and viral Vif activity.
(canceled)
A drug delivery device comprising:
- a) a first container comprising a SET domain-containing methyltransferase inhibitor that reactivates latent immunodeficiency virus transcription;
- and
- b) a second container comprising an agent that inhibits an immunodeficiency virus function selected from viral replication, viral protease activity, viral reverse transcriptase activity, viral entry into a cell, viral integrase activity, viral Rev activity, viral Tat activity, viral Nef activity, viral Vpr activity, viral Vpu activity, and viral Vif activity.
-48 (canceled)
-59 (canceled)
Dependencies are inferred from the claim text.